Medullary Thyroid Cancer research hub
4 indexed studies · 0 currently recruiting
- active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
This study is testing a new drug called selpercatinib for a type of thyroid cancer that has spread or can't be removed by surgery. It wants to see if this new drug is safer and works better than current treatments for people with a specific gene change (RET mutation).
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This study looks at a new medicine called Selpercatinib for children and young people (ages 6 months to 21 years) with certain advanced solid tumours or brain tumours. It's for those whose tumours have a specific genetic change (called RET alteration).
United States · Australia · Canada - active not recruitingPHASE4
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
This study looks at two different doses of a drug called cabozantinib for a type of thyroid cancer called medullary thyroid cancer (MTC) that has spread and is getting worse. We want to see if a lower dose works just as well with fewer side effects.
Australia · Canada · Croatia - active not recruitingPHASE1, PHASE2
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This study looks at a new drug, selpercatinib, for advanced cancers, including certain lung, thyroid, and other solid tumours that have a specific genetic change called a RET alteration. Researchers want to check its safety, how it works in the body, and if it helps shrink tumours.
United States · Australia · Canada